Method of treating osteoarthritis with an antibody to ngf
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsLynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
Life of this patent
Estimating the term…
Abstract
Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
Claims17
A method for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NO:
- 4, 20, 24, 28, 44 and 48.
A method of treating, inhibiting or ameliorating at least one symptom associated with osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy and light chain complementary determining region (HCDR and LCDR) from a HCVR/LCVR sequence pair selected from the group consisting of SEQ ID NO:
- 4/12, 20/22, 24/26, 28/36, 44/46 and 48/50.
(canceled)
(canceled)
A method of treating, inhibiting or ameliorating at least one symptom associated with osteoarthritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount an antibody or antigen-binding fragment thereof comprising a HCDR3 domain selected from the group consisting of SEQ ID NO:
- 10 and 34, and a LCDR3 domain selected from the group consisting of SEQ ID NO:
- 18 and 42.
Dependencies are inferred from the claim text.